中国肺癌杂志2026，Vol.29Issue(7)：475-490,16.DOI:10.3779/j.issn.1009-3419.2026.102.18
基于分子分型的广泛期小细胞肺癌免疫治疗专家共识
Expert Consensus on Immunotherapy for Extensive-stage Small Cell Lung Cancer Based on Molecular Subtyping
摘要
Abstract
Immune checkpoint inhibitors combined with Platinum-based Etopositde chemotherapy have become the first-line standard treatment for extensive-stage small cell lung cancer(ES-SCLC).However,treatment benefit varies sub-stantially among patients,and the proportion of long-term survivors remains limited.In recent years,the molecular classifica-tion framework comprising SCLC-A,SCLC-N,SCLC-P and SCLC-I,based on the expression patterns of ASCL1,NEUROD1 and POU2F3 as well as immune-inflammatory status,has provided a new basis for understanding the heterogeneity of im-munotherapy response and for developing precision stratified treatment in ES-SCLC.To standardize the clinical translation of molecular subtyping in ES-SCLC immunotherapy,this consensus was developed by multidisciplinary experts from respiratory medicine,oncology,pathology,radiation oncology,and basic medical sciences.Based on domestic and international evidence and clinical experience,the consensus provides recommendations on key issues,including first-line immunotherapy for ES-SCLC,molecular subtyping systems and immune microenvironment characteristics,testing and implementation pathways,immunotherapy-related biomarkers,subtype-informed treatment strategies,and dynamic monitoring.This consensus empha-sizes that molecular subtyping should currently be positioned as a tool for biological and clinical research stratification based on standard treatment,and should not be used as an independent basis for treatment decisions.Immunohistochemistry can serve as an important method for qualified centers to conduct subtyping exploration and translational research.The SCLC-I subtype may provide a useful reference for biomarker-based stratification and immunotherapy benefit prediction.For different subtypes,delta-like ligand 3(DLL3)-targeted therapy,epigenetic regulation,the MYC/AURKAaxis,and poly(ADP-ribose)polymerase(PARP)inhibitors can be important choices for subsequent treatment optimization.This consensus aims to stan-dardize pathological testing and clinical application of molecular subtyping in ES-SCLC,facilitate stratified management and individualized treatment optimization based on molecular subtypes,and provide a foundation for building a precision immu-notherapy system.关键词
肺肿瘤/分子分型/免疫治疗/病理检测/专家共识Key words
Lung neoplasms/Molecular subtyping/Immunotherapy/Pathological testing/Expert consensus引用本文复制引用
中国临床肿瘤学会肿瘤生物标志物专家委员会,浙江省抗癌协会肿瘤呼吸病学专业委员会,周建娅..基于分子分型的广泛期小细胞肺癌免疫治疗专家共识[J].中国肺癌杂志,2026,29(7):475-490,16.基金项目
本文受浙江省科学技术厅"尖兵领雁+X"科技计划项目(No.2025C02094、No.2023C03069)、国家自然科学基金项目(No.82573076)及非传染性慢性疾病-国家科技重大专项(No.2026ZD0555906)资助 This paper was supported by the grants from the Key Research and Development Program of Zhejiang Province(No.2025C02094,to Jingjing QU （No.2025C02094、No.2023C03069）
No.2023C03069,to Jianya ZHOU),National Natural Science Foundation of China(No.82573076,to Jingjing QU)and Noncommunicable Chronic Diseases-National Science and Technology Major Project(No.2026ZD0555906,to Jianya ZHOU). （No.82573076,to Jingjing QU）
